Abstract
BackgroundMyeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow (BM). Classical MPNs are classified into chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This classification is based on the presence of Philadelphia (Ph) chromosome (BCR/ABL1). CML is BCR/ABL1-positive while PV, ET, and PMF are negative. JAK2 p. Val617Phe pathological variant is the most associated mutation in BCR/ABL1-negative MPNs. The frequency of JAK2 p. Val617Phe is 90–95% in PV patients, 50–60% in ET, and 40–50% in patients with PMF. Studies on MPL gene led to the revelation of a gain of function pathological variants in JAK2 p. Val617Phe-negative myeloproliferative neoplasms (MPNs). MPL p. W515 L/K pathological variants are the most common across all mutations in MPL gene. The prevalence of these pathological variants over the Egyptian population is not clear enough. In the present study, we aimed to investigate the prevalence of MPL p. W515 L/K pathological variants in the Philadelphia (Ph)-negative MPNs over the Egyptian population.ResultsWe have tested 60 patients with Ph-negative MPNs for MPL p. W515 L/K pathological variants. Median age was 51 (22–73) years. No MPL p. W515 L/K pathological variants were detected among our patients. JAK2 p. Val617Phe in PV and PMF patients showed significantly lower frequency than other studies. Splenomegaly was significantly higher in ET patients compared to other studies.ConclusionMPL p. W515 L/K pathological variants are rare across the Egyptian Ph-negative MPNs, and further studies on a large number are recommended. MPN patients in Egypt are younger compared to different ethnic groups.
Highlights
Myeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow (BM)
Myeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow where there is a myeloid cell lineage proliferation that leads to an increase in the numbers of erythrocytes, megakaryocytes, or granulocytes in the bloodstream
Val617Phe is 90–95% of patients meeting the clinical criteria for polycythemia vera (PV), 50–60% for essential thrombocythemia (ET), and 40–50% for primary myelofibrosis (PMF) [5]
Summary
Myeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow (BM). Classical MPNs are classified into chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) This classification is based on the presence of Philadelphia (Ph) chromosome (BCR/ABL1). Val617Phe pathological variant is the most associated mutation in BCR/ABL1-negative MPNs. The frequency of JAK2 p. Myeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow where there is a myeloid cell lineage proliferation that leads to an increase in the numbers of erythrocytes, megakaryocytes, or granulocytes in the bloodstream [1] Classical MPNs include chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) according to the World Health Organization (WHO) 2008 classification and the 2016 revision [2, 3]. Val617Phe is the most associated mutation in BCR/ABL1-negative MPNs. The frequency of JAK2 p.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.